Active Clinical Trials

SAVI-PCI is currently enrolling patients.


New Prescribing Information

Download Prescribing Information

AGGRASTAT (tirofiban HCl)

Updated Indication

Aggrastat® is indicated to reduce the rate of thrombotic cardiovascular events (combined endpoint of death, myocardial infarction, or refractory ischemia/repeat cardiac procedure) in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).

Recommended Dosing Regimen

NEW Aggrastat High-Dose Bolus (HDB): Administer intravenously 25 mcg/kg over 3 minutes and then 0.15 mcg/kg/min for up to 18 hours. In patients with creatinine clearance ≤60 mL/min, give 25 mcg/kg over 3 minutes and then 0.075 mcg/kg/min.

In clinical studies using the HDB regimen, Aggrastat was administered in combination with aspirin, clopidogrel and heparin or bivalirudin to over 8,000 patients for typically ≤24 hours.

Platelet Aggregation Inhibition

The HDB regimen achieves >90% inhibition of platelet aggregation within 10 minutes of bolus administration.1

Aggrastat HDB is recommended in the following guidelines:

  • ACC/AHA Guideline for UA/NSTEMI2
  • ACC/AHA/SCAI Guideline for PCI3

Product Inquiries

Medical Information:

Product Specialist:


  • Known hypersensitivity to any component of Aggrastat
  • History of thrombocytopenia with prior exposure to Aggrastat
  • Active internal bleeding, or history of bleeding diathesis, major surgical procedure or severe physical trauma within previous month

Warnings and Precautions

  • Aggrastat can cause serious bleeding. If bleeding cannot be controlled discontinue Aggrastat.
  • Thrombocytopenia: Discontinue Aggrastat and heparin

Adverse Reactions

  • Bleeding is the most commonly reported adverse reaction


  1. Mardikar HM et al. Am Heart J 2007;154:344e1-344e5
  2. Jneid H et al. 2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction. Circulation 2012;14;126:875-910
  3. Levine GN et al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. Circulation 2011;124:e574-e651